Extended Data Fig. 1: Five-year survival analysis for the whole patient cohort and according to pathologic response subgroup for the confirmation-cohort OpACIN-neo. | Nature Medicine

Extended Data Fig. 1: Five-year survival analysis for the whole patient cohort and according to pathologic response subgroup for the confirmation-cohort OpACIN-neo.

From: Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial

Extended Data Fig. 1

a-e, Kaplan Meier curve of all patients, including the 95% confidence intervals (CI) for event free survival (n = 86) (a), relapse-free survival (n = 83) (b), distant metastases-free survival (n = 83) (c), overall survival (n = 86) (d), melanoma specific survival (from registration to melanoma related death) (n = 83) (e). f-h, Kaplan Meier curves including log-rank P value, sub grouped according to pathologic response (major pathologic response, MPR), pathologic partial response, pPR; pathologic non-response, pNR) of relapse-free survival (n = 83) (f), distant metastases-free survival (n = 83) (g), and melanoma specific survival (from surgery to melanoma related death) (n = 80) (h).

Back to article page